Independent prognostication and therapy monitoring of breast cancer patients by DNA/RNA typing of minimal residual cancer cells.
Clinical relevance, purification techniques and molecular characterization of minimal residual cancer cells (MRCC) is a controversial topic in the literature. An analytical concept including a novel isolation procedure and a panel of tests for DNA and RNA typing of MRCCs is described and clinically evaluated in this paper. The purification procedure exploiting the physical characteristics of MRCCs shows superior performance leading to > 50% pure and viable tumor cells. Proof of the presence and purity of MRCCs in an isolated sample is given by multiparametric DNA typing (amplifications, mutations, losses of heterozygosity). On the basis of the proven presence of MRCCs tumor-relevant mRNAs can be adequately analyzed by normalized quantitative real-time RT-PCR. The molecular characterization of MRCCs isolated from blood of breast cancer patients could have a strong clinical impact on prognostication, drug targeting and therapy monitoring.
Giesing
M
M
Institute for Molecular NanoTechnology, Recklinghausen, Germany.
Austrup
F
F
Böckmann
B
B
Driesel
G
G
Eder
C
C
Kusiak
I
I
Suchy
B
B
Uciechowski
P
P
Grill
H J
HJ
D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D015331:Cohort Studies; D004273:DNA, Neoplasm / Q000032:analysis; D018572:Disease-Free Survival; D005260:Female; D005819:Genetic Markers; D006801:Humans; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D012189:Retrospective Studies; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D005819:Genetic Markers; D012333:RNA, Messenger; D012334:RNA, Neoplasm